Incannex Healthcare
Incannex is a science-led combination medicines company focused on rapidly developing novel oral fixed-dose treatments and therapeutic regimens for people living with challenging chronic conditions. They aim to significantly improve the lives of those suffering from conditions like obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder through innovative cannabinoid-based and psychedelic-based medicines. Their strategy involves leveraging smart drug combinations and partnerships to bring these treatments to the forefront of patient care.
Industries
Nr. of Employees
small (1-50)
Incannex Healthcare
Incannex Healthcare Inc., 123 Innovation Drive, City, Country
Products
Oral fixed-dose combination (acetazolamide + synthetic cannabinoid) for obstructive sleep apnea
An oral fixed-dose combination formulation designed to reduce Apnea–Hypopnea Index by combining a carbonic anhydrase inhibitor with a synthetic cannabinoid to act on complementary respiratory and airway mechanisms; currently in Phase 2/3 clinical development.
Oral fixed-dose combination (synthetic cannabidiol + hydroxychloroquine) for rheumatoid arthritis
An oral fixed-dose combination designed to target immune and inflammatory pathways by combining a cannabidiol derivative with an established disease-modifying antirheumatic drug; advanced to Phase 2 clinical evaluation.
Oral synthetic psilocybin administered with psychological support for generalized anxiety disorder
An oral synthetic psychedelic compound administered alongside structured psychological support, under study as a treatment for generalized anxiety disorder with Phase 2 data showing a proportion of patients achieving clinically meaningful anxiety reduction.
Oral fixed-dose combination (acetazolamide + synthetic cannabinoid) for obstructive sleep apnea
An oral fixed-dose combination formulation designed to reduce Apnea–Hypopnea Index by combining a carbonic anhydrase inhibitor with a synthetic cannabinoid to act on complementary respiratory and airway mechanisms; currently in Phase 2/3 clinical development.
Oral fixed-dose combination (synthetic cannabidiol + hydroxychloroquine) for rheumatoid arthritis
An oral fixed-dose combination designed to target immune and inflammatory pathways by combining a cannabidiol derivative with an established disease-modifying antirheumatic drug; advanced to Phase 2 clinical evaluation.
Oral synthetic psilocybin administered with psychological support for generalized anxiety disorder
An oral synthetic psychedelic compound administered alongside structured psychological support, under study as a treatment for generalized anxiety disorder with Phase 2 data showing a proportion of patients achieving clinically meaningful anxiety reduction.
Services
Design and operational execution of clinical studies including Phase 1 safety/PK, Phase 2 proof-of-concept and Phase 2/3 randomized double-blind efficacy and safety trials across multiple indications and geographies.
Collaborative partnerships and licensing/business development to advance clinical-stage assets and explore additional therapeutic areas.
Design and operational execution of clinical studies including Phase 1 safety/PK, Phase 2 proof-of-concept and Phase 2/3 randomized double-blind efficacy and safety trials across multiple indications and geographies.
Collaborative partnerships and licensing/business development to advance clinical-stage assets and explore additional therapeutic areas.
Expertise Areas
- Combination drug development
- Clinical trial management (Phase 1–3)
- Pharmacokinetics and bioequivalence studies
- Cannabinoid-based therapeutics
Key Technologies
- Oral fixed-dose combination formulation
- Pharmacokinetic (PK) analysis
- Randomized double-blind trial design
- Crossover and dose-comparison trial designs
News & Updates
A 560-patient, randomized, double-blind safety and efficacy study started dosing in May 2024. The trial aims to evaluate the effectiveness of IHL-42X in treating obstructive sleep apnea.
A pharmacokinetics and safety study with 114 subjects was completed in July 2024.
A crossover, safety and efficacy study has been completed.
A 128-patient, double-blind study started dosing in January 2024.
A 36-patient Phase 1 safety and pharmacokinetics study has been completed.
A 94-patient, double-blind, safety and efficacy study.
A 560-patient, randomized, double-blind safety and efficacy study started dosing in May 2024. The trial aims to evaluate the effectiveness of IHL-42X in treating obstructive sleep apnea.
A pharmacokinetics and safety study with 114 subjects was completed in July 2024.
A crossover, safety and efficacy study has been completed.
A 128-patient, double-blind study started dosing in January 2024.
A 36-patient Phase 1 safety and pharmacokinetics study has been completed.
A 94-patient, double-blind, safety and efficacy study.